



Prescription Pharmaceutical Products

PRODUCT	INDICATION ^{1,3}	TERRITORY ²						PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	Others	
Oncology/Hematology								
Tafasitamab	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)		Q1-24	Submitted	Submitted	Submitted	Pre-registration	Incyte
Pemigatinib	Metastatic cholangiocarcinoma		Submitted	Submitted	Submitted	Submitted	Pre-registration	Incyte
Akynzeo®	Prevention of chemotherapy-induced acute and delayed nausea and vomiting	Q4-22	Q3-22	Q3-22				Helsinn
Aloxi®	Prevention of acute nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy	Q4-22						Helsinn
Fostamatinib	Treatment of chronic immune thrombocytopenia		Submitted	Pre-registration	Submitted	Submitted		Rigel
Nerlynx®	Extended adjuvant breast cancer and metastatic breast cancer	Q4-19						Puma
Trelstar®	Advanced prostate cancer	Q2-20						Debiopharm
Vidaza®	Myelodysplastic syndrome		Q2-10					Celgene (BMS)
Abraxane®	Metastatic pancreatic cancer		Q4-17					Celgene (BMS)
Halaven®	Metastatic breast cancer and soft tissue sarcoma		Q4-17	Q4-19	Q2-22		Marketed	Eisai
Lenvima®	Differentiated thyroid cancer and unresectable hepatocellular carcinoma		Q4-17		Q1-22		Marketed	Eisai
Lenvima®	Advanced renal cell cancer		Q4-17				Marketed	Eisai
BGx								
Ladevina®	Multiple myeloma; myelodysplastic syndrome			2011	Q3-19		Marketed	Own
Ladevina®	Mantle Cell Lymphoma; follicular lymphoma			2011			Marketed	Own
Zyvalix®	Metastatic prostate cancer			2014	Q2-18		Marketed	Own
Karfib®	Relapsed or refractory multiple myeloma			Q4-19	Approved		Marketed	Own
Leprid®	Palliative treatment of advanced prostate cancer			2007				Own
Rembre®	Chronic myeloid leukemia			2013	Q1-22		Marketed	Own
Palbocil®, Bapocil®	Breast cancer			Q1-23	Submitted		Approved	Own
Xetrane®	Multiple myeloma			Q2-19	Submitted		Approved	Own
Xetrane®	AIDS-related Kaposi sarcoma			Q2-22				Own

^{1.} The products listed as "Pre-registration" have not yet been submitted for regulatory review and products in "Submitted" are currently under regulatory review. The indication for all products classified as "Pre-registration" or "Submitted" is the anticipated indication upon regulatory approval.

^{2.} The products with an associated date are currently marketed by Knight in the respective territory. The information provided represents the date when the product was launched by Knight or when it was acquired or in-licensed by Knight if such products had existing sales.

^{3.} The products listed as "Approved" have been approved by regulatory authorities but not yet commercially launched.



PRODUCT	INDICATION ^{1,2}	TERRITORY ³						PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	Others	
Infectious Diseases								
AmBisome®	Invasive fungal infection		1997					Gilead
Cresemba®	Invasive fungal infection		Q2-20	Q3-19	Q3-19	Q2-19	Marketed	Basilea
Impavido®	Leishmaniasis						Marketed	Own
BGx								
Dolufevir®	HIV infection			Q2-21				Own
Other Specialty								
Exelon®	Symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease	Q2-21	Q2-21	Q2-21	Q2-21	Q2-21	Marketed	Own
Ibsrela®	IBS-C	Q1-21						Ardelyx
Salofalk®	Ulcerative colitis			2007	Pre-2019		Marketed	Dr. Falk
Ursofalk®	Primary biliary cirrhosis			2007	Pre-2019		Marketed	Dr. Falk
Imvexxy®	Moderate-to-severe dyspareunia	Q1-24						TXMD
Bijuva®	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24						TXMD
BGx								
Fibridoner®	Idiopathic pulmonary fibrosis			2017			Marketed	Own
Toliscriin® DPI	Pseudomonas aeruginosa lung infection in patients with cystic fibrosis			2017			Marketed	Own
Toliscriin® 1-2	Severe acute or resistant chronic infections due to colistin sensitive strains of gram-negative pathogenic bacilli			2017			Marketed	Own
Tobradosa Haler®	Chronic lung infections due to Pseudomonas aeruginosa			2018			Marketed	Own

^{1.} The products listed as "Pre-registration" have not yet been submitted for regulatory review and products in "Submitted" are currently under regulatory review. The indication for all products classified as "Pre-registration" or "Submitted" is the anticipated indication upon regulatory approval.

^{2.} The products with an associated date are currently marketed by Knight in the respective territory. The information provided represents the date when the product was launched by Knight or when it was acquired or in-licensed by Knight if such products had existing sales.

^{3.} The products listed as "Approved" have been approved by regulatory authorities but not yet commercially launched.



Pipeline and Products in Early Launch Stage

PRODUCT	INDICATION OR THERAPEUTIC AREA ^{1,3}	TERRITORY ²						LAUNCH / EXPECTED LAUNCH YEAR
		Canada	Brazil	Argentina	Colombia	Mexico	Others	
Oncology/Hematology								
Minjuvi® (tafasitamab)	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)		Q1-24	Submitted	Submitted	Submitted	Pre-registration	2024 -2025
Pemigatinib	Metastatic cholangiocarcinoma		Submitted	Submitted	Submitted	Submitted	Pre-registration	2025-2026
Fostamatinib	Treatment of chronic immune thrombocytopenia		Pre-registration	Pre-registration	Submitted	Submitted		2025-2026
Palbocil®, Bapocil®	Breast Cancer				Submitted		Approved	2025
Xetrane®	Multiple myeloma				Submitted		Approved	2025
Karfib®	Relapsed or refractory multiple myeloma				Approved			2025
Rembre®	Chronic myeloid leukemia						Submitted	2024
O501	Oncology/Hematology			Development				2025
O502	Oncology/Hematology			Development				2025
H401	Oncology/Hematology		Development		Development	Development		2026 - 2027
H402	Oncology/Hematology		Development					2028 - 2029
Other Specialty								
Imvexxy®	Moderate-to-severe dyspareunia	Q1-24						2024
Bijuva®	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24						2024
IPX203	Parkinson's disease	Pre-registration	Pre-registration	Pre-registration	Pre-registration	Pre-registration	Pre-registration	2027-2028
Qelbree™	Attention-Deficit Hyperactivity Disorder (ADHD)	Pre-registration						2026-2027
C401 (CNS)	Other Specialty		Development	Development	Submitted		Development	2025 - 2026
C402/403 (CNS)	Other Specialty		Development		Development	Development		2026 - 2027

^{1.} The products listed as "Pre-registration" have not yet been submitted for regulatory review and products in "Submitted" are currently under regulatory review. The indication for all products classified as "Pre-registration" or "Submitted" is the anticipated indication upon regulatory approval.

^{2.} The products with an associated date are currently marketed by Knight in the respective territory. The information provided represents the date when the product was launched by Knight or when it was acquired or in-licensed by Knight if such products had existing sales.

^{3.} The products listed as "Approved" have been approved by regulatory authorities but not yet commercially launched.